Abstract 736P
Background
Only limited data exist on the management of residual masses in men who have received two lines of chemotherapy for advanced seminoma. Therefore, the role of FDG PET/CT scans, surgery and other additional treatments remains controversial in these men.
Methods
Data from men with pure seminoma and residual masses after salvage chemotherapy were retrospectively collected from 13 high-volume centers. We analyzed the clinical management of residual masses (imaging, surgery, pathological data, and additional treatment modalities) and long-term outcomes. Residual mass was defined as a lesion of ≥1 cm after two lines of platinum-based chemotherapy.
Results
Data from 92 patients (pts) with non-progressing residual masses after second-line chemotherapy have been collected and have been included in this analysis. A post-chemotherapy FDG PET/CT was performed in 54 (59%) pts. Viable seminoma was found in 3/12 pts who had a biopsy (bio+). Surgery was performed in 47 (51%) pts, irrespectively of FDG uptake (no=8, yes=16). Complete necrosis was found in 42 (89%), viable seminoma in 3 (6%), teratoma in 1, and leiomyoma in 1 pt, respectively. No viable tumor cells were found in 8 men with a negative PET (PET-) who underwent surgery (2bio+). 16/28 pts with a positive PET (PET+) underwent surgery: 12 complete necrosis, 2 viable seminoma, 1 teratoma, and 1 leiomyoma. Among those with a PET+, 5/28 pts (18%) experienced either viable seminoma in residual subsequent relapse. A second relapse occurred in 13/92 (14%). Only 4/47 (8%) pts who had residual masses resected post 1st salvage chemotherapy subsequently relapsed (3 had viable seminoma in the residuals). At a median follow-up of 4.35 years, 88 (92%) pts were alive. 4/92 patients died of cancer progression.
Conclusions
Most men with seminoma residual masses after 1st salvage chemotherapy may achieve a cure. Pending validation with more pts in this rare situation, FDG PET/CT may help guide the selection of post-chemotherapy resection candidates. PET/CT appears of high negative predictive value when negative (100% [95%CI 63-100]), while PET+ scans have a remarkable risk of being false positive (positive predictive value 16% [95%CI 3-40]).
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
G. Baciarello: Financial Interests, Personal, Invited Speaker: Astellas; Financial Interests, Institutional, Steering Committee Member: Bayer; Non-Financial Interests, Principal Investigator: Roche, Eli Lilly, MSD; Non-Financial Interests, Member: ASCO. U.F.F. De Giorgi: Financial Interests, Personal, Advisory Board: Pfizer, BMS, MSD, PharmaMar, Astellas, Bayer, Ipsen, Novartis, Eisai, Janssen; Financial Interests, Personal, Invited Speaker: Roche, BMS, Clovis Oncology, AstraZeneca; Financial Interests, Institutional, Research Grant: AstraZeneca, Sanofi, Roche. G. Gravis: Financial Interests, Institutional, Invited Speaker: AAA, Amgen, Astellas, BMS, Janssen, MSD, Pfizer, Ipsen, AstraZeneca, alliance Merck Pfizer, Bayer, EISAI; Financial Interests, Institutional, Advisory Board: Alliance Merck-Pfizer, BMS, Janssen, Pfizer, Ipsen, Bayer, Eisai; Non-Financial Interests, Principal Investigator: BMS, Ipsen, Merck; Financial Interests, Institutional, Funding: Janssen; Financial Interests, Institutional, Coordinating PI: BMS. F. Morelli: Financial Interests, Personal, Invited Speaker: Astellas, Ipsen; Financial Interests, Personal, Advisory Board: Pfizer. D. Pouessel: Financial Interests, Personal, Invited Speaker: Ipsen, Bristol-Myers-Squibb, AstraZeneca, Astellas Pharma, MSD Oncology, Pfizer / Astellas; Financial Interests, Personal, Advisory Board: Astellas Pharma, Pfizer, MSD Oncology, Bristol-Myers-Squibb, Merck; Financial Interests, Institutional, Local PI: Merck Sharp & Dohme, Roche, Bristol-Myers-Squibb, AstraZeneca, Seagen. C. Oing: Financial Interests, Personal, Invited Speaker, Renal Cancer Expert Panel Case Presentation: Ipsen; Financial Interests, Personal, Invited Speaker, Talk on Pain Management in GU Cancer Patients: Medac; Financial Interests, Personal, Invited Speaker, Case Presentation Soft Tissue Sarcoma: Roche; Financial Interests, Personal, Advisory Board, Ad Board on discussing novel educational events for young haematologists: Novartis; Financial Interests, Personal, Invited Speaker, Science Slam with a presentation on young professional support from oncological societies in Germany: AstraZeneca; Financial Interests, Personal, Advisory Board, AdBoard assessing educational needs for oncology professionals regarding G-CSF use: Sandoz; Financial Interests, Personal, Invited Speaker, Presentation on Burnout and Resilience in medical oncology professionals: Asklepios Hamburg; Financial Interests, Personal, Advisory Board, Larotrectinib use in sarcoma: Bayer; Financial Interests, Personal, Advisory Board, Experiences with Cabo/Nivo as first-line treatment for metastatic RCC: Ipsen; Non-Financial Interests, Other, Clinical Advisory role in early drug discovery with a fellowship position affiliated with Astex Pharmaceuticals, Cambridge, UK: Astex Pharmaceuticals; Non-Financial Interests, Institutional, Product Samples, Cytotoxic Agent for Preclinical Experiments: PharmaMar. S. Ladoire: Financial Interests, Personal, Advisory Board, advisory board: Pfizer, Novartis, AstraZeneca, Sanofi, Daiichi Sankyo, Gilead, Menarini-Stemline; Financial Interests, Personal, Advisory Board, advisory board, expert testimony: Astellas; Financial Interests, Personal, Advisory Board, expert testimony, invited speaker: Janssen, Ipsen; Financial Interests, Personal, Invited Speaker, invited speaker: BMS, Seagen, Exact Science; Financial Interests, Personal, Invited Speaker, invited speaker, expert testimony: Lilly; Financial Interests, Institutional, Research Grant, research grant: Novartis, Eisai, BMS. K. Fizazi: Financial Interests, Institutional, Advisory Board: Astellas, Bayer, Janssen, AAA, MSD, AstraZeneca, Novartis/AAA, Pfizer, Daiichi Sankyo; Financial Interests, Institutional, Invited Speaker: Astellas, Bayer, Janssen, Sanofi, MSD, AstraZeneca, Novartis, Pfizer; Financial Interests, Personal, Advisory Board: Curevac, Orion; Financial Interests, Personal, Advisory Board, February 2022: Arvinas; Financial Interests, Personal, Advisory Board, April 2022: Macrogenics; Financial Interests, Institutional, Research Grant, Trial chair: Pfizer, Bayer, AstraZeneca, Orion, MSD, BMS, Janssen; Non-Financial Interests, Principal Investigator, Chair of the 7DX phase 3 trial: BMS; Non-Financial Interests, Principal Investigator, Chair of the Docetaxel-pembrolizumab phase 3 trial: Merck; Non-Financial Interests, Principal Investigator, Chair of the Darolutamide BCR phase 3 trial: Bayer; Non-Financial Interests, Principal Investigator, Chair of the PSMAfore phase 3 trial: AAA/Novartis; Non-Financial Interests, Principal Investigator, Chair of the CYPIDES ODM-208 Phase I-II trial: Orion; Non-Financial Interests, Principal Investigator, Chair of the STESIDES ODM-209 Phase I-II trial: Orion; Non-Financial Interests, Principal Investigator, Chair of the CAPITELLO 281 phase 3 trial: AstraZeneca; Non-Financial Interests, Principal Investigator, Chair of the TALAPRO-2 and TALAPRO-3 phase 3 trials: Pfizer; Non-Financial Interests, Principal Investigator, Chair of the RADIANT phase 3 trial: Bayer; Non-Financial Interests, Principal Investigator, Chair of the TRITON-3 phase 3 trial: Clovis. All other authors have declared no conflicts of interest.
Resources from the same session
968P - High sensitivity routine blood based detection of HCC: An AI model from 220k patients
Presenter: Kin Nam Kwok
Session: Poster session 18
969P - Establishing a novel routine blood component signature for Hepatocellular Carcinoma (HCC) screening with big clinical data
Presenter: Ka Man Cheung
Session: Poster session 18
970P - Real-world multi-center study of systemic treatment after first-line atezolizumab plus bevacizumab for advanced hepatocellular carcinoma in Asia-Pacific countries
Presenter: Choong-kun Lee
Session: Poster session 18
971P - Effect of preoperative frailty on surgical outcomes following hepatic resection for elderly patients with hepatocellular carcinoma: A multicenter retrospective cohort study from China
Presenter: Zhongqi Fan
Session: Poster session 18
972P - Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in advanced hepatocellular carcinoma
Presenter: Mara Persano
Session: Poster session 18
973P - Clinicopathologic and treatment outcome data in 165 fibrolamellar carcinoma patients
Presenter: Sunyoung Lee
Session: Poster session 18
974P - The barthel index predicts surgical textbook outcomes following hepatectomy for elderly patients with hepatocellular carcinoma: A multicenter cohort study from China
Presenter: Guoyue Lv
Session: Poster session 18
975P - The clinical impact of urinary protein creatinine ratio and AFP at six weeks in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab
Presenter: Kaoru Tsuchiya
Session: Poster session 18
976P - Overall survival in advanced hepatocellular carcinoma treated with concomitant systemic therapy and stereotactic radiation therapy or systemic therapy alone
Presenter: Alexander Piening
Session: Poster session 18